Skip to main content
Clinical Trials/NCT01029691
NCT01029691
Completed
Not Applicable

Use of PAP in Women With Pre-eclampsia

University of Michigan1 site in 1 country125 target enrollmentMay 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Preeclampsia
Sponsor
University of Michigan
Enrollment
125
Locations
1
Primary Endpoint
Severity of Sleep Disordered Breathing
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to identify whether sleep-disordered breathing - as measured by overnight polysomnography - is associated with pre-eclampsia and to determine whether use of positive airway pressure can improve nocturnal blood pressure.

Detailed Description

Initial enrollment began with only women with a pre-existing diagnosis of pre-eclampsia. Part way through the study, IRB granted approval to expand recruitment to include other hypertensive diagnoses. So, in effect, a more accurate post hoc title would be Study of Positive Airway Pressure to Reduce Blood Pressure in Hypertensive Pregnancies.

Registry
clinicaltrials.gov
Start Date
May 2009
End Date
May 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Louise O'Brien

Associate Professor

University of Michigan

Eligibility Criteria

Inclusion Criteria

  • Women with preeclampsia who receive care at the University of Michigan Hospitals
  • No current use of PAP therapy.
  • Willing and able to provide informed consent.

Exclusion Criteria

  • Current PAP therapy
  • Any medical reason why PAP therapy may not be suitable (e.g., in patients with recent head trauma).
  • Cognitively impaired and unable to understand informed consent.

Outcomes

Primary Outcomes

Severity of Sleep Disordered Breathing

Time Frame: at baseline

Severity of sleep disordered breathing, using the apnea/hypopnea index (number of respiratory evens per hour of sleep), among participants who have or do not have nocturnal hypertension. Obstructive sleep apnea is typically considered present if the AHI is at least 5.

Nocturnal Blood Pressure

Time Frame: baseline and 1 week after PAP treatment.

measured by a 24 hour cuff, averaged across the night;

Number of Participants With Worsening of Hypertension

Time Frame: 1-6 months after enrollment.

This outcome measure's purpose was to look at the impact of the APAP on blood pressure. This was done categorically by looking at worsening of hypertension with or without escalation of antihypertensive medications.

Number of Participants With Sleep-disordered Breathing (SDB)

Time Frame: Baseline night 1

Presence or absence of SDB (defined as an apnea/hypopnea index; AHI\>=5)

Secondary Outcomes

  • Gestational Age at Delivery(At delivery (within 6 months of enrollment).)
  • NICU Admission(at delivery (within 6 months of enrollment))
  • Birth Weight(At delivery (within 6 months of enrollment))

Study Sites (1)

Loading locations...

Similar Trials